RenovoRx, Inc. Common Stock Status update

Great. Thank you, Justin. I appreciate the opportunity here with JonesTrading, and thank you, Dr. Sridhar and Dr. Kim for joining today's KOL webinar. My name is Shaun Bagai, CEO of RenovoRx. I have spent my whole career in the medical technology space, with the hopes of helping create and then creating disruptive technologies that will really change the landscape of medicine. It looks like with RenovoRx, after 12 years of hard work, this is starting to finally come to fruition. As a very high level, when we think about cancer care and cancer therapy, it is about balancing what we do to the patients versus what we do to the tumor. Unfortunately, a lot of modern medicine really destroys the patient in the process of trying to kill the tumor.

We found a way to do that completely differently, where there may be an opportunity here where we can actually tackle the tumor and have the patients not have the same toxicities and side effects. With that, I will give you a small, short background and then turn it over to the physicians to really dive into details about how they see this in their practice. To start at high level, our disclaimers, disclosures, forward-looking statements are on our website. Just start at high level about what we are tackling and how that works. When we think about tumors, we often think about balls of tumor cells fed by a lot of blood vessels, and that is the case with many cancers in the body, like liver tumors, for example.

As a background, on the left panel, we see a cartoon image of a liver tumor that has a large blood vessel that feeds directly into the liver tumor. Many tumors in the body don't have a large blood supply and don't have these large tumor feeders, like pancreatic tumors, for example. In this case, the tumor cells are fed very slowly. There's not a big blood vessel that feeds the tumor itself. The tumor grows slowly. It actually gets necrotic on the inside, and there's a lot of fibrotic dead tissue. What this does is cause almost a barrier to chemotherapy success, where not a lot of chemotherapy gets into the tumor, causing results not to be fantastic. We overcome this via what we call a Trans-Arterial Micro-Perfusion that utilizes our RenovoCath device.

This is FDA-cleared for the delivery of chemotherapy and other therapeutics, and I'll talk about really quickly how that works in patients. When you think of systemic chemotherapy, again, we're giving current standard of care through the veins, and it really traverses the whole body, causing a lot of side effects, of course, and very little gets to tumors like pancreatic tumors. We do get some effects, in liver tumors, for example, where you do have that large blood feeder vessel going to the tumor, with the side effects. But unfortunately, in pancreatic tumors, glioblastoma, non-small cell lung cancers, bile duct cancers, and sarcomas, you don't get a high concentration of drug in the tumor because they don't have as large connection to the blood supply. Via our Trans-Arterial Micro-Perfusion system, or TAMP, a physician's able to position our RenovoCath device adjacent to the tumor using X-ray guidance.

The patients are in and out of the operating room and out of the hospital usually in a day in an outpatient setting. It's just a small little incision, about 2 millimeters, to go to the patient's leg artery fed adjacent to the tumor. Then using the proprietary nature of our device, they can blow up 2 soft balloons and isolate blood flow adjacent to a tumor and then deliver a full dose and volume of therapy. Imagine a liter of fluid going into a small space that's about 1 to 2 milliliters in volume over 20 minutes, causing a pressure head, then forcing the agent through the blood vessel wall without causing much damage, and then actually traversing the tissue and saturating the tumor in chemotherapy.

What we end up seeing is about 100 times the dose at the tissue site than you would if you gave systemically, really causing a potential efficacy effect on the tumor and hopefully massively reducing side effects in patients. Just to touch on data we've shown in the past, we did have a phase III trial, a TIGeR-PaC study. We actually completed enrollment very recently, and we were able to share the interim results of the first interim analysis back in 2023, earlier in the trial. This was presented at ESMO GI. Two of the major findings we saw is we saw a 65% reduction in toxicities and side effects in these tumors, these patients. What you're seeing here is almost across the board, we see a reduction in all the common side effects you see with systemic chemotherapy when delivered locally via the TAMP mechanism.

This is one of the biggest drivers of interest from physicians and patients on wanting to go for this therapy is because of that reduction in toxicity. On the flip side, we did see a trend towards a survival benefit. The preliminary data actually showed a separation of curves, where in this first 30% look, we saw a six-month separation where patients were living six months longer, almost double as long as what you'd expect with just standard of care systemic chemotherapy. This is an interim look. It didn't hit significance yet, but trending, but it gives us a glimpse of a possibility of what this technology could do as we wait for final trial data.

But what's interesting is the RenovoCath being 510(k) cleared is actually being picked up commercially, and patients are being treated because of that promise that there's a chance of longer living, and more importantly, in some circumstances, that reduction of toxicity and side effects. So with that, I'll hand it back to Justin, and we can hear from the physicians on their usage and thought process around this technology.